2020
Medicare Prescription Drug Plan Coverage of Hormone Therapies Used by Transgender Individuals
Solotke MT, Liu P, Dhruva SS, Gulanski B, Shah ND, Ross JS. Medicare Prescription Drug Plan Coverage of Hormone Therapies Used by Transgender Individuals. LGBT Health 2020, 7: 137-145. PMID: 32267818, DOI: 10.1089/lgbt.2019.0306.Peer-Reviewed Original ResearchMeSH KeywordsFemaleGonadal Steroid HormonesHormone Replacement TherapyHumansInsurance CoverageMaleMedicarePrescription DrugsTransgender PersonsUnited States
2003
Association of Endogenous Sex Hormones and Insulin Resistance among Postmenopausal Women: Results from the Postmenopausal Estrogen/Progestin Intervention Trial
Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI. Association of Endogenous Sex Hormones and Insulin Resistance among Postmenopausal Women: Results from the Postmenopausal Estrogen/Progestin Intervention Trial. The Journal Of Clinical Endocrinology & Metabolism 2003, 88: 1646-1652. PMID: 12679451, DOI: 10.1210/jc.2002-021375.Peer-Reviewed Original ResearchMeSH KeywordsAdipose TissueAgedBiological AvailabilityBody CompositionBody ConstitutionBody Mass IndexEstradiolEstrogen Replacement TherapyFemaleGonadal Steroid HormonesHomeostasisHumansInsulin ResistanceLogistic ModelsMiddle AgedPostmenopauseProgestinsSex Hormone-Binding GlobulinTestosteroneVisceraConceptsBody mass indexInsulin resistanceBioavailable testosteroneBioavailable estradiolPostmenopausal womenTotal estradiolMass indexSex hormonesPostmenopausal Estrogen/Progestin Interventions (PEPI) TrialHomeostasis model assessment-IRLower SHBG levelsYounger postmenopausal womenYr of menopauseHomeostasis model assessmentHormone replacement therapyEndogenous sex hormonesModel assessment-IRDose-response fashionCross-sectional associationsLogistic regression analysisSHBG levelsTotal testosteroneVisceral adiposityHighest quartileTotal adiposity